True North Therapeutics bags $22 mln Series A

South San Francisco-based biotech firm True North Therapeutics has closed $22 million in Series A funding. The investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures and Baxter Ventures.

Zytoprotec Secures Funds from Baxter Ventures

Zytoprotec, a company developing novel peritoneal dialysis solutions and other treatments based on active cytoprotection, has raised 2 million euros ($2.7 million) from new investor Baxter Ventures. The funding goes towards a 4 million euros Series A financing.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget